X4 PHARMACEUTICALS INC's ticker is XFOR and the CUSIP is 98420X103. A total of 65 filers reported holding X4 PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,941,401 | -62.7% | 3,615,964 | -33.7% | 0.00% | -60.0% |
| Q2 2023 | $10,576,124 | +1125019.6% | 5,451,610 | +404.7% | 0.01% | +400.0% |
| Q1 2023 | $940 | -17.9% | 1,080,213 | -6.3% | 0.00% | 0.0% |
| Q4 2022 | $1,145 | -99.4% | 1,153,433 | +921.1% | 0.00% | – |
| Q3 2022 | $193,000 | +157.3% | 112,964 | +45.4% | 0.00% | – |
| Q2 2022 | $75,000 | -89.4% | 77,687 | -80.8% | 0.00% | – |
| Q1 2022 | $707,000 | +52.4% | 403,946 | +99.5% | 0.00% | – |
| Q4 2021 | $464,000 | -67.2% | 202,483 | -24.3% | 0.00% | -100.0% |
| Q3 2021 | $1,414,000 | -43.6% | 267,368 | -30.7% | 0.00% | -50.0% |
| Q2 2021 | $2,509,000 | +1420.6% | 386,007 | +2232.9% | 0.00% | – |
| Q1 2020 | $165,000 | -76.8% | 16,546 | -75.1% | 0.00% | -100.0% |
| Q4 2019 | $710,000 | -70.4% | 66,341 | -64.8% | 0.00% | -75.0% |
| Q3 2019 | $2,397,000 | +5.4% | 188,625 | +24.4% | 0.00% | +33.3% |
| Q2 2019 | $2,275,000 | – | 151,636 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 311,492 | $2,109,000 | 3.48% |
| SV Health Investors, LLC | 311,490 | $2,109,000 | 1.07% |
| Bain Capital Life Sciences Investors, LLC | 1,648,485 | $11,160,000 | 1.04% |
| New Leaf Venture Partners, L.L.C. | 335,000 | $2,268,000 | 0.91% |
| Ikarian Capital, LLC | 724,680 | $4,907,000 | 0.36% |
| BVF INC/IL | 792,892 | $5,368,000 | 0.29% |
| Opaleye Management Inc. | 75,000 | $508,000 | 0.10% |
| Orbimed Advisors | 1,086,493 | $7,356,000 | 0.09% |
| RA Capital Management | 559,494 | $3,788,000 | 0.07% |
| Bleichroeder LP | 35,730 | $242,000 | 0.04% |